Pradigastat is primarily investigated for its potential in treating dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. It functions as a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, which plays a crucial role in triglyceride synthesis. By inhibiting DGAT1, it helps reduce the production of triglycerides, thereby lowering their levels in the bloodstream. This mechanism makes it a promising candidate for managing conditions like hypertriglyceridemia and other lipid metabolism disorders. Additionally, its application is being explored in addressing obesity and related metabolic syndromes, as it may contribute to improved lipid profiles and overall metabolic health. Clinical studies are ongoing to evaluate its efficacy and safety in these therapeutic areas.